IDEAYA Biosciences, Inc. Payments to Acquire Debt Securities, Available-for-sale
IDEAYA Biosciences, Inc. (IDYA) reported Payments to Acquire Debt Securities, Available-for-sale of $356.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $313.43M, a 145.73% increase year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $42.61M, a 59.50% decline year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $236.14M, a 29.94% decline year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $138.99M, a 34.97% decline year-over-year.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $607.89M, a 48.97% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.19B, a 99.89% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $595.98M, a 132.98% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $255.81M, a 18.79% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $313.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $356.04M 10-Q · filed 2026-08-04 | $592.18M derived: sum of 3 quarters · filed 2026-08-04 | $731.17M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $42.61M 10-Q · filed 2026-05-05 | $278.75M derived: sum of 2 quarters · filed 2026-05-05 | $417.74M derived: sum of 3 quarters · filed 2026-05-05 | $545.29M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $236.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $375.13M derived: sum of 2 quarters · filed 2026-02-17 | $502.68M derived: sum of 3 quarters · filed 2026-08-04 | $607.89M 10-K · filed 2026-02-17 |
| 2025-09-30 | $138.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $266.54M derived: sum of 2 quarters · filed 2026-08-04 | $371.75M 10-Q · filed 2025-11-04 | $708.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $127.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $232.76M 10-Q · filed 2026-08-04 | $569.80M derived: sum of 3 quarters · filed 2026-08-04 | $783.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $105.21M 10-Q · filed 2026-05-05 | $442.25M derived: sum of 2 quarters · filed 2026-05-05 | $655.97M derived: sum of 3 quarters · filed 2026-05-05 | $820.74M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $337.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $550.76M derived: sum of 2 quarters · filed 2026-02-17 | $715.53M derived: sum of 3 quarters · filed 2026-02-17 | $1.19B 10-K · filed 2026-02-17 |
| 2024-09-30 | $213.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $378.49M derived: sum of 2 quarters · filed 2025-11-04 | $854.27M 10-Q · filed 2025-11-04 | $1.08B derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $164.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $640.54M 10-Q · filed 2025-08-05 | $862.15M derived: sum of 3 quarters · filed 2026-02-17 | $943.98M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $475.78M 10-Q · filed 2025-05-06 | $697.39M derived: sum of 2 quarters · filed 2026-02-17 | $779.22M derived: sum of 3 quarters · filed 2026-02-17 | $999.47M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $221.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $303.44M derived: sum of 2 quarters · filed 2026-02-17 | $523.68M derived: sum of 3 quarters · filed 2026-02-17 | $595.98M 10-K · filed 2026-02-17 |
| 2023-09-30 | $81.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $302.08M derived: sum of 2 quarters · filed 2024-11-04 | $374.38M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $220.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $292.54M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $72.30M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $255.81M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $315.00M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |